Welcome to Multibagg AI
Log in to access personalized features
Bearish
5
Neutral
6
Bullish
3
Bearish
28
Neutral
6
Bullish
12
Bearish
23
Neutral
0
Bullish
9
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
147.40 | 1,591 Cr | 387.89 | 1.59 | 0.00 | 0.45 | 6.06 | 0.23 | |
81.84 | 1,335 Cr | 36.70 | 7.33 | 0.00 | 16.69 | 19.54 | 12.23 | |
121.45 | 1,060 Cr | 23.27 | 5.35 | 2.71 | 26.36 | 23.95 | 0.00 | |
109.10 | 859 Cr | 58.97 | 3.10 | 0.00 | 36.29 | 39.11 | 0.00 | |
80.36 | 588 Cr | 25.76 | 4.31 | 0.00 | 39.91 | 39.92 | — | |
321.55 | 498 Cr | 32.71 | 4.75 | 0.00 | 19.24 | 34.76 | 21.01 | |
195.00 | 415 Cr | 24.19 | 3.45 | 0.00 | 0.00 | 0.00 | 10.42 |
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
GPT Healthcare Ltd (GPTHEALTH) is currently trading at 125.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
GPT Healthcare Limited operates a chain of multispecialty hospitals in Eastern India, focusing on providing tertiary care services. Its core business includes specialties like oncology, cardiology, and nephrology with a strong presence in cities like Kolkata, Agartala, and Raipur. The company's revenue reached INR 350.5 Cr for 9M FY26, marking a robust year-on-year growth of 12.12%. Despite this, EBITDA margins have come under pressure, declining to 18.6%, impacted by new hospital expansions. The launch of new facilities like the Raipur hospital, commissioned with state-of-the-art technology for renal transplants and oncology, is enhancing GPT's service offerings and scaling operations. GPT Healthcare emphasizes technology-driven healthcare innovation, boasting a high ARPOB and integrating robotic surgeries across its hospitals, notably in Salt Lake and Howrah, reflecting its strategic focus on advanced treatments. The company is targeting expansion to a 1,000-bed network by FY27, with plans for new hospitals in Jamshedpur and beyond, underscoring aggressive capacity growth strategy in Eastern India.
Over the past 52 weeks, GPT Healthcare Ltd has traded between a low of ₹119.25 and a high of ₹184.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
GPT Healthcare Ltd has a market capitalization of approximately 1,059.74. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
GPT Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 23.95 and operates in the Healthcare sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,059.74 Cr, GPT Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
GPT Healthcare Ltd operates in the Healthcare sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of GPT Healthcare Ltd is 23.95. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
GPT Healthcare Limited operates a chain of multispecialty hospitals in Eastern India, focusing on providing tertiary care services. Its core business includes specialties like oncology, cardiology, and nephrology with a strong presence in cities like Kolkata, Agartala, and Raipur.
The company's revenue reached INR 350.5 Cr for 9M FY26, marking a robust year-on-year growth of 12.12%. Despite this, EBITDA margins have come under pressure, declining to 18.6%, impacted by new hospital expansions.
The launch of new facilities like the Raipur hospital, commissioned with state-of-the-art technology for renal transplants and oncology, is enhancing GPT's service offerings and scaling operations.
GPT Healthcare emphasizes technology-driven healthcare innovation, boasting a high ARPOB and integrating robotic surgeries across its hospitals, notably in Salt Lake and Howrah, reflecting its strategic focus on advanced treatments.
The company is targeting expansion to a 1,000-bed network by FY27, with plans for new hospitals in Jamshedpur and beyond, underscoring aggressive capacity growth strategy in Eastern India.
Healthcare
Hospitals / Medical Services
1,060 Cr
Low Risk
23.9
60.2
0.9
5.4
184.80
119.25
Sales CAGR
Profit CAGR
ROE
ROCE
